Alcon Introduces AcrySof IQ PanOptix Trifocal IOL in the US, the First and Only FDA-Approved Trifocal Lens

Source: Alcon

Alcon announced the FDA approval and the initial commercial launch of the AcrySof IQ PanOptix Trifocal IOL, the first and only trifocal lens approved in the United States. PanOptix is clinically shown to deliver an exceptional combination of near, intermediate, and distance vision while reducing the need for glasses after surgery, according to an Alcon news release.

PanOptix is one of the leading presbyopia-correcting IOLs in more than 70 countries. It is designed for today’s active lifestyles, from viewing mobile devices and computer screens to high-quality distance vision in a range of lighting conditions. The new lens uses Enlighten Optical Technology, a proprietary design that optimizes intermediate vision without compromising near and distance vision. Available in spherical and toric designs, PanOptix is built on Alcon’s AcrySof IQ IOL platform that has been implanted in more than 120 million eyes globally.

“We are proud to bring this new class of IOLs to the largest eye care market in the world,” David J. Endicott, Chief Executive Officer of Alcon, said in a company news release. “We are leveraging Alcon’s years of experience with PanOptix in other countries to provide the best possible training and support for U.S. surgeons. Our goal is to ensure optimal outcomes for cataract patients looking to correct their vision at all distances, with the vast majority of them never needing to wear glasses post-surgery.”

The FDA approval of PanOptix was based on a pivotal study at 12 investigational sites in the United States. With this single trifocal lens design, PanOptix patients demonstrated exceptional, uninterrupted vision. The results also showed high patient satisfaction with more than 99% of PanOptix patients saying they would choose the same lens again.1

“The U.S. ophthalmology community has been eagerly awaiting FDA approval of PanOptix. While participating in the clinical trial, I saw first-hand the impact of this lens on my patients,” Kerry Solomon, MD, Carolina Eyecare Physicians, PanOptix clinical trial investigator, said in the news release. “We know patients undergoing cataract surgery today want a replacement lens that delivers the vision they need to live full, active lives without always being dependent on glasses. PanOptix is an excellent lens option to address these needs and is clinically proven to deliver an outstanding range of vision.”

Alcon plans to begin training U.S. ophthalmologists and making inventory of PanOptix and PanOptix Toric IOLs available through the rest of 2019 into early 2020.

As part of its patient education efforts, the company will soon launch a dedicated PanOptix website and multimedia awareness campaign. A similar effort is planned for eye care professionals with special launch activities slated for the annual meeting of the American Academy of Ophthalmology in October.

1 AcrySof IQ PanOptix Directions For Use.

Related Content